Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633885 | 0.91 | CHRM4 (0.46) | DRD2SIGMAR1ACHEBCHEGPR88 | |
| SCHEMBL3024605 | 0.88 | NAMPT (0.50) | MEN1KMT2ACTSSCTSKDRD2 | |
| SCHEMBL22151315 | 0.85 | SLC6A9 (0.44) | MEN1KMT2AGAACTSSCTSK | |
| SCHEMBL5074958 | 0.82 | KMT2A (0.44) | MEN1KMT2ADRD2CNR1CNR2 | |
| SCHEMBL8298777 | 0.81 | CKS1B (0.51) | DRD2NAMPT | |
| SCHEMBL5744529 | 0.80 | RIPK1 (0.43) | MEN1KMT2AGAACTSSCTSK | |
| SCHEMBL23745899 | 0.80 | TLR2 (0.53) | SIGMAR1CNR2NAMPT | |
| SCHEMBL2793927 | 0.79 | KMT2A (0.49) | MEN1KMT2A | |
| SCHEMBL17726230 | 0.79 | KMT2A (0.45) | MEN1KMT2AGAA | |
| SCHEMBL1094296 | 0.78 | KMT2A (0.44) | MEN1KMT2AGAAACHECNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984627-B1 | Peptide derivatives | ASTRAZENECA AB (SE) | 2006-01-10 | — | — | US | disclosed |
| US-20050222395-A1 | New peptide derivatives | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-0701568-B1 | NEW PEPTIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-04-25 | — | — | EP | disclosed |
| EP-1067136-A1 | New peptide derivatives | AstraZeneca AB (SE) | 2001-01-10 | — | — | EP | disclosed |
| CN-1278530-A | Novel peptide derivative | ASTRA AB (SE) | 2001-01-03 | — | — | CN | disclosed |
| US-5939392-A | THROMBIN INHIBITORS, ANTICOAGULANTS AND ANTIINFLAMMATORY AGENTS | ASTRA AKTIEBOLAG (SE) | 1999-08-17 | — | — | US | disclosed |
| US-5856307-A | Peptide derivatives as kininogenase inhibitors | ASTRA AKTIEBOLAG (SE) | 1999-01-05 | — | — | US | disclosed |
| US-5783563-A | Method for treatment or prophylaxis of venous thrombosis | ASTRA AKTIEBOLAG | 1998-07-21 | — | — | US | disclosed |
| US-5780631-A | ANTICOAGLUANT | ASTRA AKTIEBOLAG (SE) | 1998-07-14 | — | — | US | disclosed |
| US-5723444-A | ENZYME INHIBITORS AND ANTICOAGULANTS | ASTRA AB (SE) | 1998-03-03 | — | — | US | disclosed |
| US-5602253-A | STARTING MATERIAL FOR SERINE PROTEASE INHIBITORS | AKTIEBOLAGET ASTRA (SE) | 1997-02-11 | — | — | US | disclosed |
| EP-0701568-A1 | NEW PEPTIDE DERIVATIVES | Astra Aktiebolag (SE) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994029336-A1 | NEW PEPTIDE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222395-A1 | New peptide derivatives | SERPINE1, SERPINC1, SPINT2 | MEN1 1137/4885KMT2A 4410/4885GAA 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.